Search - tctmd.com

Displaying 421 - 440 of 1581

Sort: Relevancy | Date

Presentation TCT 2023

TRILUMINATE Pivotal Imaging Substudy: Insights from CT and MRI

Presenter: Joao Cavalcante

October 25, 2023

Presentation TCT 2023

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation: The Tri-QOL Study

Presenter: Suzanne Arnold

October 25, 2023

Presentation TCT 2023

Long-term Clinical Outcomes After iFR vs. FFR Guided Coronary Revascularization – Insights From the SWEDEHEART National Registry

Presenter: Matthias Götberg

October 25, 2023

Presentation TCT 2023

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

Presenter: Ron miller

October 25, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

Presentation TCT 2023

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Presenter: Giovanni Esposito

October 25, 2023

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Presentation TCT 2023

Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Drug-Eluting Stent In-Stent Restenosis: A Prospective, Multicenter, Randomized Trial

Presenter: Shao-Liang Chen

October 25, 2023

Presentation TCT 2023

Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial

Presenter: Giovanni De Maria

October 25, 2023

Presentation TCT 2023

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

Presenter: Myeong-Ki Hong

October 25, 2023

Presentation TCT 2023

Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Presenter: Robert Yeh

October 25, 2023

Presentation TCT 2023

Wearable HF Monitoring Devices: Landscape Overview, Patient Indications, and Implementation Science

Presenter: Liviu Klein

October 25, 2023

Presentation TCT 2023

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Presenter: Ramon Varcoe

October 25, 2023

Presentation TCT 2023

The Conundrum of Clinical Trials in Cardiogenic Shock

Presenter: Navin Kapur

October 25, 2023

Presentation TCT 2023

The Psychology of Improvement

Presenter: Kalaivani Mahadevan

October 25, 2023

Presentation TCT 2023

Acute Decompensated HF Trials: Who Should be Enrolled and What Should the Study Endpoints Be?

Presenter: JoAnn Lindenfeld

October 25, 2023

Presentation TCT 2023

Intelligent Interventions: Personalized Medicine for VTEs (FlowMedical)

Presenter: Jonathan Paul

October 25, 2023

Presentation TCT 2023

PROs Alone in Non-Blinded Studies Shouldn’t Drive Device Approval

Presenter: Nir Uriel

October 25, 2023

Presentation TCT 2023

Deep Vein Arterialization for No-Option CLTI Patients: Technology and Clinical Program Update

Presenter: Mehdi Shishehbor

October 25, 2023

Presentation TCT 2023

PROs are a Powerful Endpoint in TR Interventional Trials

Presenter: Suzanne Arnold

October 25, 2023

Advertisement

TRILUMINATE Pivotal Imaging Substudy: Insights from CT and MRI

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation: The Tri-QOL Study

Long-term Clinical Outcomes After iFR vs. FFR Guided Coronary Revascularization – Insights From the SWEDEHEART National Registry

TCT 244: Impact of Online Educational Series on Interventional Innovations in Blood Pressure Control

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Drug-Eluting Stent In-Stent Restenosis: A Prospective, Multicenter, Randomized Trial

Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Wearable HF Monitoring Devices: Landscape Overview, Patient Indications, and Implementation Science

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

The Conundrum of Clinical Trials in Cardiogenic Shock

The Psychology of Improvement

Acute Decompensated HF Trials: Who Should be Enrolled and What Should the Study Endpoints Be?

Intelligent Interventions: Personalized Medicine for VTEs (FlowMedical)

PROs Alone in Non-Blinded Studies Shouldn’t Drive Device Approval

Deep Vein Arterialization for No-Option CLTI Patients: Technology and Clinical Program Update

PROs are a Powerful Endpoint in TR Interventional Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content